Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors

Patent metadata

Field	Value
Publication number	US-10463649-B2
Application number	US-201615580991-A
Country	US
Kind code	B2
Filing date	Jun 6, 2016
Priority date	Jun 8, 2015
Publication date	Nov 5, 2019
Grant date	Nov 5, 2019

Abstract

The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.

First claim

The invention claimed is:

1. A composition for inhibiting melanoma growth or reducing the size of a solid tumor that is melanoma or extending the life span of a subject that has melanoma or inducing apoptosis of melanoma cells, the composition comprising:
at least one of a MAPK pathway protein, a mutant MAPK pathway protein, or a MAPK pathway protein kinase; and
an Mcl-1 inhibitor selected from at least one of:

2. The composition of claim 1 , wherein the MAPK pathway protein is selected from at least one of wild type or mutated BRAF, CRAF, MEK 1, MEK 2, ERK1, ERK2, NRAS, and KRAS.

3. The composition of claim 1 , further comprising one or more Mcl-1 inhibitors selected from at least one of an antibody that blocks Mcl-1 activity, omacetaxine mepesuccinate, 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (Seliciclib), a small interfering RNA (siRNA) or a small hairpin RNA (shRNA) that inhibits expression of Mcl-1, antagonists of Mcl-1 isotype 1, agonists of Mcl-1 isotype 2, benzylisothiocyanate, phenethylisothiocyanate, diindolyl methane, curcumin, piperlongumine, Marinopyrrole A, Cucurbitacin B, Capsaicin, Penfluridol, Perphenazine, Bcl-2 inhibitors, Bcl-2 siRNA/shRNA, Bcl-XL inhibitors, Bcl-XL siRNA/shRNA and any other Bcl-2 family inhibitors, a small interfering RNA (siRNA) that inhibits expression of Mcl-1, or a salt thereof.

4. The composition of claim 1 , wherein the MAPK pathway protein or kinase inhibitor is selected from at least one of GDC-0879, PLX-4720, Sorafenib Tosylate, Dabrafenib, Trametinib, LGX818, Vemurafenib, or a salt thereof.

5. The composition of claim 1 , further comprising one or more other anti-cancer agents.

6. The composition of claim 1 , wherein the cells of the tumors or tumor metastases are relatively insensitive or refractory to treatment with the inhibitor of the MAPK pathway protein, the mutant MAPK pathway protein, or the MAPK pathway protein kinase as a single agent.

7. The composition of claim 1 , wherein the MAPK pathway protein is a wild type or a mutated BRAF and the inhibitor of the BRAF is a small interfering RNA (siRNA) that inhibits expression of BRAF or a small molecule that reduces the overall BRAF activity in a cell.

8. The composition of claim 1 , wherein the tumor is insensitive to the inhibitor of the MAPK pathway protein, the mutant MAPK pathway protein, or the MAPK pathway protein kinase administered alone.

9. The composition of claim 1 , wherein the tumor that overexpresses Mcl-1 is a primary tumor, or a tumor metastasis.

Assignees

• Univ Texas Tech System

Inventors

• Srivastava Sanjay K
• Fofaria Neel M

Classifications

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• C07D235/28

  Sulfur atoms · CPC title

• A61K31/341

  not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine · CPC title

• A61K31/4184 Primary

  condensed with carbocyclic rings, e.g. benzimidazoles · CPC title

• C07D233/60

  with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms · CPC title